Comparative Pharmacology
Head-to-head clinical analysis: BACITRACIN ZINC NEOMYCIN SULFATE POLYMYXIN B SULFATE versus GENTAFAIR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BACITRACIN ZINC NEOMYCIN SULFATE POLYMYXIN B SULFATE versus GENTAFAIR.
BACITRACIN ZINC-NEOMYCIN SULFATE-POLYMYXIN B SULFATE vs GENTAFAIR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bacitracin zinc inhibits bacterial cell wall synthesis by interfering with dephosphorylation of the lipid carrier that transports peptidoglycan precursors. Neomycin sulfate and polymyxin B sulfate are aminoglycoside and polypeptide antibiotics, respectively; neomycin binds to 30S ribosomal subunit and causes misreading of mRNA, while polymyxin B disrupts bacterial cell membrane permeability by interacting with phospholipids.
Gentamicin is an aminoglycoside antibiotic that binds to the 30S ribosomal subunit of susceptible bacteria, inhibiting protein synthesis and causing misreading of mRNA, leading to cell death.
Apply topically (ointment or cream) to affected area 1-3 times daily. For ophthalmic use, instill 1-2 drops into affected eye(s) every 3-4 hours.
Gentamicin 3-5 mg/kg IV or IM once daily for serious infections; alternatively, 1.5-2 mg/kg IV or IM every 8 hours.
None Documented
None Documented
Neomycin: 2-3 h; polymyxin B: 4.5-6 h; bacitracin: 1.5 h. Combined: effectively ~2-6 h depending on renal function; clinical context: prolonged with renal impairment.
2-3 hours (normal renal function); may extend to 24-48 hours in severe renal impairment, necessitating dose adjustment.
Neomycin: ~99% renal; polymyxin B: ~60% renal, 40% fecal; bacitracin: mainly renal (over 90%). Combined: renal (predominant), with minor biliary/fecal contribution (polymyxin B).
Renal: over 90% unchanged via glomerular filtration; minor biliary (<1%).
Category A/B
Category C
Aminoglycoside Antibiotic
Aminoglycoside Antibiotic